摘要
目的 探讨血浆循环核酸 p5 3基因突变检测的可行性 ,研究乳腺癌患者循环核酸 p5 3基因突变对于乳腺癌发生、发展和预后估计的临床意义 .方法 应用聚合酶链反应(PCR)扩增 p5 3基因外显子 5～ 8,并用变性高效液相色谱技术 (DHPL C)分析产物突变情况 ,再与各生物学参数进行了相关研究 .结果 33例患者中 14例 (42 .4 % ) p5 3基因突变 ,且突变率与组织分化级别、ER阴性显著相关 (P<0 .0 5 ) ,与临床分期和淋巴结及远处转移情况无关 .结论 DHPL C可作为一种快速简便的基因突变检测手段 ,p5 3基因突变在乳腺癌循环核酸中有较高的检出率并预示肿瘤的恶性程度 ,血浆基因突变有望成为简便的预后参考指标 .
AIM To evaluate the presence of tumor DNA in plasma and study the clinical significance of p53 gene mutations associated with the development and prognostic signifi cance in breast cancer. METHODS Extraction of DNA from patients' plasma and the target DNA fragments were amplified by PCR. The production were analyzed by denaturing high performance liquid chromatography (DHPLC). The mutation status obtained by DHPLC was confirmed by DNA sequencing. RESULTS The total p53 gene exon 5 to exon 8 mutation rate was 42.4% (14/33). There were statistically significant associations between p53 gene mutation and histological grade, ER(-) ( P <0.05), but no significant association was found between mutation and clinical stages or metastasis. CONCLUSION P53 gene exon 5 to 8 can be amplified in breast cancer patients' plasma DNA. DHPLC is an accurate, rapid and economic way to screen mutation in plasma DNA amplified fragment, and plasma DNA mutation detection by this method offers a new approach for prognosis.
出处
《第四军医大学学报》
北大核心
2002年第9期835-837,共3页
Journal of the Fourth Military Medical University
基金
全国高校优秀青年教师教学科研奖励计划资助 (TRA-POYT99-16)
高等学校骨干教师计划资助 (FUKT2 0 0 0 -0 6)
